Barinthus Biotherapeutics plc. (BRNS)
↓ Download CSV- Sector Manufacturing
- Incorporated X0
- Fiscal year ends Dec 31
In fiscal 2025, Barinthus Biotherapeutics plc. reported revenue of $0, down 100.0% from the prior year. The company ran a net loss. It held $98.17M in total assets against $23.88M in total liabilities.
Key ratios (FY2025)
-89.4%
Return on equity
-100.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $14.97M | $802.0K | $44.70M | $268.0K | $4.82M | — |
| Operating Income | -$70.56M | -$67.97M | -$83.91M | -$4.04M | -$45.22M | -$20.05M | — |
| Net Income | -$66.43M | -$61.07M | -$73.35M | $5.34M | -$50.87M | -$17.71M | — |
| EPS (Diluted) | $-1.64 | $-1.55 | $-1.91 | $0.14 | $-1.96 | $-2.24 | — |
| Total Assets | $98.17M | $160.33M | $214.51M | $270.20M | $280.71M | $50.67M | — |
| Total Liabilities | $23.88M | $30.19M | $27.51M | $27.00M | $28.15M | $53.81M | — |
| Shareholders' Equity | $74.29M | $130.13M | $187.00M | $243.20M | $252.56M | -$36.91M | -$22.08M |
| Cash & Equivalents | $70.46M | $110.66M | $142.09M | $194.38M | $214.05M | $43.27M | — |
| Operating Cash Flow | -$47.98M | -$28.94M | -$50.92M | -$14.43M | -$32.58M | -$11.03M | — |
| Capital Expenditures | $37.0K | $892.0K | $5.41M | $6.14M | $1.15M | $293.0K | — |
| Shares Outstanding | 40.85M | 40.23M | 38.64M | 37.68M | 37.19M | 7.96M | — |